|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
15.950 -0.380 (-2.327%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 282,799,605 | -1.134% | 286,042,998 | 294,726,810 | 300,950,280 | 261,471,723 |
| Cost of Sales | (263,728,126) | -0.741% | (265,696,092) | (272,783,515) | (277,679,599) | (239,814,229) |
| Gross Profit | 19,071,479 | -6.268% | 20,346,906 | 21,943,295 | 23,270,681 | 21,657,494 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (987,599) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | 20,932 | -70.818% | 71,728 | (175,995) | 128,201 | 38,093 | |
| Share of Results of Asso. & JCEs | 587,105 | -14.647% | 687,853 | 624,719 | 574,277 | 492,880 | |
| Profit / (Loss) before Taxation | 6,944,889 | -3.676% | 7,209,893 | 7,596,489 | 8,866,031 | 8,003,672 | |
| Taxation | (1,765,086) | -5.744% | (1,872,648) | (1,697,273) | (1,972,800) | (1,775,054) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,776,030) | -5.104% | (1,871,559) | (2,195,341) | (2,788,792) | (2,534,874) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,403,773 | -1.786% | 3,465,686 | 3,703,875 | 4,104,439 | 3,693,744 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 808,716 | -18.753% | 995,377 | 1,073,865 | 1,417,830 | 1,584,310 |
| Depreciation & Amortisation | 1,995,892 | -10.634% | 2,233,389 | 2,325,197 | 2,099,806 | 2,000,685 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 109.000 | -1.802% | 111.000 | 119.000 | 132.000 | 118.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 27.300 | -- | 25.710 | 24.207 | 22.304 | 20.265 |
| Remarks: | Real time quote last updated: 25/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,403,773 |
| %Change | -1.786% |
| EPS / (LPS) | RMB 1.090 |
| NBV Per Share (¥) | RMB 27.300 |